In this study, we investigated the mRNA expression of Plk1–4 in primary cells from B-ALL patients and if treatment with Plk1-targeting siRNNs resulted in a specific Plk1 knockdown without affecting the other Plk members. This evidence concerns the gene PLK1 and acute lymphoblastic leukemia.